Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01607879 · ClinicalTrials.gov registry record · Phase 2
Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation
A Phase 2 study, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT01607879 is a Phase 2 study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 48 participants.
The verdict
NCT01607879, a Phase 2 study, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a study of HMB plus amino acids in older men with prostate cancer starting androgen deprivation therapy (ADT). The investigators hypothesize that the use of this nutritional supplementation will decrease the loss of muscle mass and strength that occurs when men start ADT.
Interventions
- DRUG Standard of care ADT + (HMB + arginine + glutamine)
- OTHER Standard of care ADT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2014-03 |
| Est. Completion | 2021-02-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01607879
The ClinicalTrials.gov registry entry for NCT01607879 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of care ADT + (HMB + arginine + glutamine) is the first listed.
NCT01607879 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01607879 about?
NCT01607879 is a clinical study titled "Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation". This is a study of HMB plus amino acids in older men with prostate cancer starting androgen deprivation therapy (ADT). The investigators hypothesize that the use of this nutritional supplementation will decrease the loss of muscle mass and strength that occurs when men start ADT.
What is the current status of trial NCT01607879?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2014-03. Estimated completion is 2021-02-16.
What interventions are being tested in trial NCT01607879?
The interventions under investigation include: Standard of care ADT + (HMB + arginine + glutamine) (DRUG), Standard of care ADT (OTHER).
Who is sponsoring clinical trial NCT01607879?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.